HERZLIYA, Israel, Dec. 1, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) (“XTL” or the “Company”), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced its financial and operational results for the three- and nine-month periods ended September 30, 2014.
Josh Levine, Chief Executive Officer of XTL, stated, “We remain focused on our drug development efforts with the in-licensing of hCDR1 for the treatment of Systemic Lupus Erythematosus, which is poised for a Phase II clinical trial. We continue with the rigorous planning process for this core asset with assistance from our Clinical Advisory Board. With their extensive knowledge of lupus and autoimmune system disorders, we still anticipate being able to present a finalized trial design to the FDA and initiate clinical trials in 2015. hCDR1 has been highlighted as an attractive potential candidate for the safe and effective treatment of Lupus. Multiple myeloma is another target market we aim to address with our rHuEPO asset. We reaffirm the 2015 timeline we had previously projected to commence Phase II for this clinical trial.”
“The strong management team has set a clear path for the Company to become a leader in drug development.
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.
